title: Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.
abstract: Buprenorphine has rarely been administered as an opioid agonist maintenance therapy in a correctional setting. This study introduced buprenorphine maintenance in a large urban jail, Rikers Island in New York City. Heroin-dependent men not enrolled in community methadone treatment and sentenced to 10-90 days in jail (N=116) were voluntarily randomly assigned either to buprenorphine or methadone maintenance, the latter being the standard of care for eligible inmates at Rikers. Buprenorphine and methadone maintenance completion rates in jail were equally high, but the buprenorphine group reported for their designated post-release treatment in the community significantly more often than did the methadone group (48% vs. 14%, p<.001). Consistent with this result, prior to release from Rikers, buprenorphine patients stated an intention to continue treatment after release more often than did methadone patients (93% vs. 44%, p<.001). Buprenorphine patients were also less likely than methadone patients to withdraw voluntarily from medication while in jail (3% vs. 16%, p<.05). There were no post-release differences between the buprenorphine and methadone groups in self-reported relapse to illicit opioid use, self-reported re-arrests, self-reported severity of crime or re-incarceration in jail. After initiating opioid agonist treatment in jail, continuing buprenorphine maintenance in the community appears to be more acceptable to offenders than continuing methadone maintenance.
authors.affiliation: The Evaluation Center, Western Michigan University, Kalamazoo, MI 49008, USA. stephen.magura@wmich.edu
authors.forename: Stephen
authors.initials: S
authors.lastname: Magura
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Lee
authors.forename: Jason
authors.initials: J
authors.lastname: Hershberger
authors.forename: Herman
authors.initials: H
authors.lastname: Joseph
authors.forename: Lisa
authors.initials: L
authors.lastname: Marsch
authors.forename: Carol
authors.initials: C
authors.lastname: Shropshire
authors.forename: Andrew
authors.initials: A
authors.lastname: Rosenblum
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002047:Buprenorphine / Q000009:adverse effects / Q000627:therapeutic use*; D017831:Diagnosis, Dual (Psychiatry); D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications / Q000523:psychology; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000523:psychology; D008691:Methadone / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009294:Narcotics / Q000009:adverse effects / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D018579:Patient Selection; D011330:Prisons; D012008:Recurrence; D012959:Socioeconomic Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone